• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

司维拉姆对肾移植后环孢素A和霉酚酸酯药代动力学的影响。

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

作者信息

Pieper Anne-Kathrin, Buhle Franziska, Bauer Steffen, Mai Ingrid, Budde Klemens, Haffner Dieter, Neumayer Hans-Hellmut, Querfeld Uwe

机构信息

Department of Pediatric Nephrology, Charité, Humboldt University, Berlin, Germany.

出版信息

Nephrol Dial Transplant. 2004 Oct;19(10):2630-3. doi: 10.1093/ndt/gfh446. Epub 2004 Aug 10.

DOI:10.1093/ndt/gfh446
PMID:15304561
Abstract

BACKGROUND

After renal transplantation, patients with insufficient graft function may require phosphate binders. It is still unknown if sevelamer, a new calcium-free phosphate binder, interferes with the uptake of immunosuppressants. We studied its effects on the pharmacokinetics of cyclosporin A (CsA) and mycophenolate mofetil.

METHODS

We examined 10 adults and eight children with stable renal graft function and stable CsA trough levels. A 12 h pharmacokinetic profile (10 observation points) was conducted without sevelamer, after a single dose and after 4 days of treatment with it. CsA levels were measured with both a monoclonal antibody assay (CEDIA) and a polyclonal antibody assay (FPIA), mycophenolic acid (MPA) levels by EMIT assay and CsA metabolites AM1, AM9 and AM4N by a modified HPLC method.

RESULTS

Sevelamer had no significant effect on CsA kinetics [area under the curve (AUC), peak concentration (C(max)), time of C(max)]. The AUC of AM1 was decreased by 30% and C(max) by 25% after 4 days of sevelamer intake. MPA levels were significantly reduced by a mean of 25% of the AUC (P<0.05) and by 30% of the C(max) after a single dose of sevelamer.

CONCLUSIONS

A single sevelamer dose reduces the C(max) and the AUC of MPA. Its intake for several days does not significantly influence CsA kinetics.

摘要

背景

肾移植后,移植肾功能不全的患者可能需要使用磷结合剂。新型无钙磷结合剂碳酸司维拉姆是否会干扰免疫抑制剂的吸收尚不清楚。我们研究了其对环孢素A(CsA)和霉酚酸酯药代动力学的影响。

方法

我们检查了10名成年和8名儿童肾移植功能稳定且CsA谷浓度稳定的患者。在未服用碳酸司维拉姆时、单剂量服用后以及服用4天后进行了12小时的药代动力学分析(10个观察点)。使用单克隆抗体测定法(CEDIA)和多克隆抗体测定法(FPIA)测量CsA水平,通过酶放大免疫测定法测量霉酚酸(MPA)水平,并通过改良的高效液相色谱法测量CsA代谢物AM1、AM9和AM4N。

结果

碳酸司维拉姆对CsA的动力学[曲线下面积(AUC)、峰浓度(C(max))、C(max)出现时间]无显著影响。服用碳酸司维拉姆4天后,AM1的AUC降低了30%,C(max)降低了25%。单剂量服用碳酸司维拉姆后,MPA水平的AUC平均显著降低25%(P<0.05),C(max)降低30%。

结论

单次服用碳酸司维拉姆可降低MPA的C(max)和AUC。连续服用数天对CsA的动力学无显著影响。

相似文献

1
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.司维拉姆对肾移植后环孢素A和霉酚酸酯药代动力学的影响。
Nephrol Dial Transplant. 2004 Oct;19(10):2630-3. doi: 10.1093/ndt/gfh446. Epub 2004 Aug 10.
2
A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.在接受含环孢素A和不含环孢素A免疫抑制方案的稳定心脏移植患者中,通过有限采样策略监测霉酚酸暴露时,测量谷浓度与简化AUC估计值的比较。
Clin Ther. 2006 Jun;28(6):893-905. doi: 10.1016/j.clinthera.2006.06.015.
3
Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.肾移植患者移植后前3个月内霉酚酸药代动力学参数的比较。
J Clin Pharm Ther. 2006 Feb;31(1):27-34. doi: 10.1111/j.1365-2710.2006.00713.x.
4
Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.预测长期服用霉酚酸酯联合环孢素或他克莫司的心脏移植患者曲线下面积的最佳单一时间点。
J Heart Lung Transplant. 2005 Oct;24(10):1614-8. doi: 10.1016/j.healun.2004.12.112.
5
Significant discrepancy in cyclosporin A post-dose concentrations when analyzed with specific RIA and HPLC method.
Int J Clin Pharmacol Ther. 2010 Feb;48(2):87-92. doi: 10.5414/cpp48087.
6
Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.霉酚酸在中国肾移植患者中的药代动力学
J Zhejiang Univ Sci B. 2005 Sep;6(9):885-91. doi: 10.1631/jzus.2005.B0885.
7
Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients.西那卡塞对肾移植受者他克莫司、环孢素和霉酚酸药代动力学的影响。
Nephrol Dial Transplant. 2008 Mar;23(3):1048-53. doi: 10.1093/ndt/gfm632. Epub 2007 Oct 23.
8
Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.霉酚酸酯在接受霉酚酸酯和环孢素治疗的稳定期儿童肝移植受者中的药代动力学。
Liver Transpl. 2007 Nov;13(11):1570-5. doi: 10.1002/lt.21274.
9
Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.采用有限采样策略同时估算稳定期肾移植受者中环孢素和霉酚酸的曲线下面积。
Eur J Clin Pharmacol. 2002 Jan;57(11):805-11. doi: 10.1007/s00228-001-0389-2.
10
Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.小儿移植受者的长期随访:霉酚酸谷浓度并非长期移植肾功能的良好指标。
Clin Transplant. 2004 Oct;18(5):576-9. doi: 10.1111/j.1399-0012.2004.00229.x.

引用本文的文献

1
Clinical Pharmacology in Sarcoidosis: How to Use and Monitor Sarcoidosis Medications.结节病的临床药理学:如何使用和监测结节病药物
J Clin Med. 2024 Feb 22;13(5):1250. doi: 10.3390/jcm13051250.
2
[Pattern of biochemical markers of mineral and bone disorders in kidney transplant recipients: real-world data].肾移植受者矿物质和骨代谢紊乱的生化标志物模式:真实世界数据
Probl Endokrinol (Mosk). 2023 May 11;69(2):47-57. doi: 10.14341/probl13167.
3
Transfer of mycophenolic acid into human milk.霉酚酸向人乳中的转移。
J Nephrol. 2023 Jul;36(6):1715-1717. doi: 10.1007/s40620-023-01672-2. Epub 2023 Jun 7.
4
Exploring co-dispensed drug use in patients on sevelamer or polystyrene sulfonate to identify potential novel binding interactions: a cross sectional in silico study : Potential novel binding interactions with resins.探索同时使用司维拉姆或聚苯乙烯磺酸的患者中的共用药情况,以确定潜在的新型结合相互作用:一项横截面计算机研究:与树脂的潜在新型结合相互作用。
Int J Clin Pharm. 2022 Apr;44(2):389-398. doi: 10.1007/s11096-021-01355-7. Epub 2021 Nov 30.
5
Binding interactions with sevelamer and polystyrene sulfonate in vitro.与司维拉姆和聚苯乙烯磺酸钠的体外结合相互作用。
Pharmacol Res Perspect. 2021 Aug;9(4):e00834. doi: 10.1002/prp2.834.
6
Intradialytic parenteral nutrition improves nutritional status in a complex cystic fibrosis patient with redo double lung transplant and end-stage renal disease.血液透析期间胃肠外营养改善了一名患有再次双肺移植和终末期肾病的复杂囊性纤维化患者的营养状况。
BMJ Case Rep. 2020 Mar 19;13(3):e233346. doi: 10.1136/bcr-2019-233346.
7
Does Sevelamer Hydrochloride (Renagel) Influence 25(Oh)D3 and 1,25(Oh)2D3 Level in Haemodialysis Patients?盐酸司维拉姆(Renagel)对血液透析患者的25(OH)D3和1,25(OH)2D3水平有影响吗?
EJIFCC. 2005 Dec 2;16(4):100-102. eCollection 2005 Dec.
8
Phosphate and FGF-23 homeostasis after kidney transplantation.肾移植后磷酸盐和 FGF-23 的动态平衡。
Nat Rev Nephrol. 2015 Nov;11(11):656-66. doi: 10.1038/nrneph.2015.153. Epub 2015 Sep 29.
9
Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.碳酸司维拉姆:用于治疗慢性肾脏病成人高磷血症的药物评价。
Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7.
10
Update and critical appraisal of sevelamer in the management of chronic renal failure.碳酸镧在慢性肾衰竭管理中的更新与批判性评估
Open Access J Urol. 2010 Sep 2;2:161-70. doi: 10.2147/OAJU.S7227.